# Buntanetap PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/buntanetap

> Buntanetap, sponsored by Annovis Bio, Inc. (ANVS): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | buntanetap |
| Codes |  |
| Sponsor | Annovis Bio, Inc. (ANVS) https://sec-api.dev/companies/anvs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug 2022: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-21, last confirmed 2025-03-21.
- SEC Form 10-K (accession 0001558370-25-003482): "In August 2022, we initiated a Phase 3 clinical trial of buntanetap in 450 early PD patients, which were separated into three cohorts of 150 patients (the "Phase 3 PD Trial")." https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003482): "With the FDA's guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our "Phase 3 PD Study")." https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm

### Feb 2023: trial start

- Status: completed. Date confidence: month. Stage: 2/3.
- First seen 2025-03-21, last confirmed 2026-03-13.
- SEC Form 10-K (accession 0001104659-26-027751): "In February 2023, we initiated a Phase 2/3 AD Trial of buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients." https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003482): "In February 2023, we initiated a Phase 2/3 clinical trial of buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients (the "Phase 2/3 AD Trial")." https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm

### Feb 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-21, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001104659-26-027751): "In February of 2025, we initiated the Phase 3 AD Trial of buntanetap in 760 early AD patients with 380 dosed and 380 placebo patients." https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003482): "In February of 2025, we initiated the Phase 3 AD study of buntanetap in 750 early AD patients, which will be separated into two cohorts of 375 patients (the "Phase 3 AD Trial")." https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028574): "In February 2025, Annovis launched a pivotal Phase 3 study (NCT06709014) evaluating buntanetap over a period of 18 months as both a symptomatic (6 months) and a potential disease-modifying (18 months) treatment in early AD patients." https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/tm268976d1_ex99.htm

### August 14, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-08-14, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-097091): "ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026." https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/buntanetap.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Buntanetap PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/buntanetap

```bibtex
@misc{secapidev_pdufa_buntanetap_20261116,
  title        = {Buntanetap PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/buntanetap}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_buntanetap_20261116","title":"Buntanetap PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/buntanetap","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
